Who Makes the Mounjaro Drug — and Why It Matters

Eli Lilly, the company behind tirzepatide and why its name is relevant to your decision

Eli Lilly and Company is headquartered in Indianapolis, Indiana, and has operated in the UK for decades. When Lilly developed tirzepatide, it was pursuing something genuinely new: a molecule that binds to both the GIP receptor and the GLP-1 receptor at the same time, rather than just one. That dual action is why Mounjaro behaves differently from earlier weight-management medicines, and it's the scientific basis for the results seen in the SURMOUNT clinical programme. The medicine was licensed in the UK by the MHRA under the brand name Mounjaro for weight management in adults and for type 2 diabetes treatment.

One misconception worth clearing up: some people assume Mounjaro and Wegovy are essentially the same product from the same company, just branded differently. They are not. Wegovy contains semaglutide and is made by Novo Nordisk, a Danish company. Tirzepatide and semaglutide work through overlapping but distinct mechanisms. If you have ever searched for who makes Mounjaro for weight loss, the answer is Lilly, which holds the intellectual property, the manufacturing process and the regulatory dossiers for tirzepatide globally. You can read more about the drug itself on the tirzepatide overview page.

Why does the manufacturer matter practically? Because the only genuine Mounjaro available through a UK pharmacy comes from Lilly's authorised supply chain. Pens sold outside that chain (through social media, unverified websites or sellers offering the product without a clinical assessment) are not sourced from Lilly and cannot be verified as authentic. The MHRA has seized large volumes of counterfeit weight-loss pens in recent years, including fake tirzepatide pens, precisely because manufacturer provenance is impossible to check when you bypass the licensed route.

What Lilly's relationship with UK pharmacies actually looks like

Eli Lilly supplies Mounjaro to the UK through its network of authorised wholesale distributors, who in turn supply GPhC-registered pharmacies. This is the licensed UK supply chain referenced in pharmacy regulation: a traceable, auditable route from manufacturing facility to the patient's door. A registered pharmacy can confirm its supplier relationship; it is not something that needs to be taken on trust.

The practical upshot for you is straightforward. When patients ask who makes Mounjaro, the answer matters because it determines whether the medicine you receive was manufactured to MHRA approval specifications: the correct formulation, stored and transported correctly, with an authenticated batch number. You can verify a pharmacy's registration on the GPhC register before you place any order, registration number 9012878 is nume's, published on the regulator's own site.

Lilly raised its UK list price for Mounjaro significantly from 1 September 2025, the highest-dose pen's list price moved from around £122 to around £330. Private providers set their own prices above that floor, and market prices since then have typically ranged roughly £149–£375 per month depending on dose and provider. If you want to understand what private treatment costs in context, the Mounjaro UK pricing page sets out how to read those figures honestly.

Lilly's ongoing responsibilities as the drug's manufacturer

Holding a UK marketing authorisation is not a one-time event. Eli Lilly is required to submit ongoing pharmacovigilance data to the MHRA (real-world safety reports from patients and healthcare professionals across the UK) as a condition of the licence. The Black Triangle (▼) status on Mounjaro reflects this active monitoring requirement: the MHRA wants additional data collected because the medicine is relatively new in widespread use.

This is also why the MHRA and NHS publish guidance that evolves. The NHS tirzepatide medicines page, for example, is updated as new safety communications emerge. Lilly is responsible for issuing updated patient information leaflets and SmPCs when the evidence base changes. The most current dosing, storage and safety detail for Mounjaro will always be in the NHS's tirzepatide medicine guide, not in any third-party summary including this one.

For patients, this ongoing manufacturer accountability is a meaningful reassurance. The SURMOUNT programme involved thousands of adults across multiple trials; the safety data that underpins the UK licence was generated under Lilly's sponsorship and submitted to regulators. That process (costly, slow and rigorous by design) is what separates a licensed medicine from an unverified compound. Understanding who make Mounjaro and what that accountability involves is covered alongside the mechanism and evidence in the Mounjaro drug explainer, if you want to go further.

Where a prescriber fits in, and how a decision about treatment gets made

Lilly manufactures the medicine. Regulators licence it. Prescribers and pharmacies form the clinical layer between those facts and any individual patient. Under UK law, Mounjaro cannot be dispensed without a valid prescription from a registered prescriber who has assessed the patient. That assessment exists to match the medicine to the person: checking BMI, medical history, current medicines, any contraindications, and eligibility under the licensed criteria.

At nume, a GPhC-registered Independent Prescriber reviews every consultation personally. Not a triage algorithm, not a chatbot, a named clinician reads your answers the same day. If the medicine is clinically appropriate, the prescription is issued and the pen is dispatched from our UK pharmacy. Our clinical team page explains who carries out that review.

Mounjaro is licensed for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds can apply for certain ethnic backgrounds under UK guidance. The full picture of eligibility, what the treatment involves and how to explore it is on the consultation page, which is the right place to start if you want to check whether treatment suits your situation. That's the decision this page has been building toward: manufacturer, supply chain, prescriber accountability, all of it leads to the same question. Is this medicine right for you? A prescriber is the person to answer it.